Product Description
Bifidobacteria Probiotics Bifidobacterium Breve for Intestinal Bacterial Colonization and in the Prevention and/or Reduction of the Incidence of Colics in Infants (Sourced from: https://clinicaltrials.gov/ct2/history/NCT03219931?V_2=View)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Azienda Ospedaliero Universitaria Maggiore della Carita
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Colic|Pediatric Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12622000153718 | N/A |
Active, not recruiting |
Respiratory Tract Infections |
2023-02-10 |
2024-08-29 |
Treatments |
|
| BIFI-OBESE | P4 |
Completed |
Pediatric Obesity |
2017-10-30 |
2019-03-21 |
Treatments |
|
| NEOBIFI | P4 |
Completed |
Colic |
2017-07-31 |
2019-03-21 |
Treatments |